Bio-Rad Laboratories, Inc. P/E Ratio 2008–2025
Bio-Rad Laboratories, Inc. reported 10.88 of price-to-earnings ratio for fiscal 2025. That was 102.8% higher than fiscal 2021. Compared with fiscal 2020, the change was +136.0%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive.
| Fiscal year | P/E Ratio | Change (YoY) |
|---|---|---|
| FY 2025 | 10.88 | — |
| FY 2024 | — | — |
| FY 2023 | — | — |
| FY 2022 | — | — |
| FY 2021 | 5.37 | +16.4% |
| FY 2020 | 4.61 | -27.4% |
| FY 2019 | 6.35 | -66.9% |
| FY 2018 | 19.19 | -67.3% |
| FY 2017 | 58.64 | -71.7% |
| FY 2016 | 207.14 | +454.2% |
| FY 2015 | 37.37 | -5.4% |
| FY 2014 | 39.53 | -14.0% |
| FY 2013 | 45.95 | +152.8% |
| FY 2012 | 18.17 | +19.0% |
| FY 2011 | 15.27 | -3.1% |
| FY 2010 | 15.76 | -15.0% |
| FY 2009 | 18.55 | -20.2% |
| FY 2008 | 23.24 | — |
Source: Bio-Rad Laboratories, Inc. SEC filings — fiscal-year-end price ÷ diluted EPS. Computed deterministically; refreshed nightly (last updated August 2, 2026). Open BIO 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Bio-Rad Laboratories, Inc. reported 10.88 of price-to-earnings ratio for fiscal 2025. That was 102.8% higher than fiscal 2021. Compared with fiscal 2020, the change was +136.0%. This is a fiscal-year-end price divided by diluted EPS—not a live valuation—and is omitted when annual EPS is not positive. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Bio-Rad Laboratories, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeBio-Rad Laboratories, Inc. — frequently asked questions
What is Bio-Rad Laboratories, Inc.'s price-to-earnings ratio?
Bio-Rad Laboratories, Inc. (BIO) reported price-to-earnings ratio of 10.88 for fiscal year 2025, per its SEC filings.
How has Bio-Rad Laboratories, Inc.'s price-to-earnings ratio changed over time?
Between fiscal 2008 and 2025, BIO's price-to-earnings ratio declined at roughly 4.4% per year (compound annual rate), from 23.24 to 10.88.
Where does this data come from?
Figures are computed from Bio-Rad Laboratories, Inc.'s official SEC filings (fiscal-year-end price ÷ diluted EPS), refreshed nightly. Not investment advice.
More BIO financial history
Full BIO fundamentals page → · Analyze price-to-earnings ratio with a free tool → · Research guide & leaders → · All 1,500+ companies →